See more : AnalytixInsight Inc. (ALY.V) Income Statement Analysis – Financial Results
Complete financial analysis of Ensysce Biosciences, Inc. (ENSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ensysce Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- International Media Acquisition Corp. (IMAQR) Income Statement Analysis – Financial Results
- Hyundai Department Store Co. Ltd. (069960.KS) Income Statement Analysis – Financial Results
- Tianshan Aluminum Group Co., Ltd. (002532.SZ) Income Statement Analysis – Financial Results
- Primary Health Properties PLC (PHP.L) Income Statement Analysis – Financial Results
- Liaoning Oxiranchem,Inc. (300082.SZ) Income Statement Analysis – Financial Results
Ensysce Biosciences, Inc. (ENSC)
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.23M | 2.52M | 3.53M | 3.93M | 1.76M | 0.00 | 0.00 |
| Cost of Revenue | 7.59M | 19.84M | 151.00 | 1.37M | 3.33M | 1.56M | 0.00 |
| Gross Profit | -5.36M | -17.31M | 3.53M | 2.56M | -1.56M | -1.56M | 0.00 |
| Gross Profit Ratio | -240.17% | -686.08% | 100.00% | 65.18% | -88.70% | 0.00% | 0.00% |
| Research & Development | 7.59M | 19.84M | 4.69M | 4.39M | 3.40M | 0.00 | 0.00 |
| General & Administrative | 5.36M | 6.91M | 18.71M | 1.15M | 6.93M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -3.60M | 0.00 | 0.00 |
| SG&A | 5.36M | 6.91M | 18.71M | 1.15M | 3.33M | 1.56M | 146.70K |
| Other Expenses | -7.59M | -2.52M | -3.53M | -3.93M | 0.00 | 600.00K | 0.00 |
| Operating Expenses | 5.36M | 24.22M | 19.87M | 1.61M | 3.33M | 959.25K | 146.70K |
| Cost & Expenses | 12.95M | 24.22M | 19.87M | 1.61M | 3.33M | 959.24K | 146.70K |
| Interest Income | 0.00 | 1.25M | 3.22M | 719.65K | 4.25M | 3.63M | 0.00 |
| Interest Expense | 353.95K | 109.53K | 1.30M | 995.50K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 151.00 | 151.00 | 201.00 | 201.00 | 161.14K | 0.00 |
| EBITDA | -10.72M | -24.22M | -19.87M | -1.61M | 921.15K | 2.68M | -27.56K |
| EBITDA Ratio | -480.52% | -959.91% | -562.71% | -41.03% | -188.70% | 0.00% | 0.00% |
| Operating Income | -10.72M | -24.22M | -19.87M | -1.61M | -3.33M | -959.24K | -146.70K |
| Operating Income Ratio | -480.52% | -959.91% | -562.71% | -41.04% | -188.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | 91.91K | 14.41K | -9.28M | 1.45M | 4.25M | 3.64M | 119.14K |
| Income Before Tax | -10.63M | -24.21M | -29.15M | -160.88K | 921.15K | 2.68M | -27.56K |
| Income Before Tax Ratio | -476.40% | -959.33% | -825.38% | -4.09% | 52.22% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 753.88K | -151.00 | 777.85K | -555.20K | 553.92K | 3.64K |
| Net Income | -10.61M | -24.96M | -29.15M | -938.73K | 1.48M | -1.34M | -31.19K |
| Net Income Ratio | -475.81% | -989.21% | -825.38% | -23.88% | 83.70% | 0.00% | 0.00% |
| EPS | -4.69 | -138.73 | -346.90 | -14.29 | 15.02 | -12.91 | -0.30 |
| EPS Diluted | -4.69 | -138.73 | -346.90 | -13.65 | 15.02 | -12.91 | -0.30 |
| Weighted Avg Shares Out | 2.26M | 179.93K | 84.02K | 65.70K | 98.26K | 104.02K | 105.00K |
| Weighted Avg Shares Out (Dil) | 2.26M | 179.93K | 84.02K | 68.78K | 98.26K | 104.02K | 105.00K |
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
Ensysce Biosciences Issues 2024 Shareholder Letter
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
Source: https://incomestatements.info
Category: Stock Reports